| abstract |
A pharmaceutical composition comprising (1) a polypeptide which is (a) a fragment of the herpes simplex virus (HSV) protein U L 49 comprising amino acids 49-57 of, respectively, HSV-2 or HSV-1: nArg Pro Arg Gly Glu Val Arg Phe Leu (SEQ ID NO: 1) or nArg Gln Arg Gly Glu Val Arg Phe Val (SEQ ID NO: 2) n nand having a length of less than 50 amino acids, or a variant of such a fragment, having a length of less than 50 amino acids and exhibiting at least 70% identity therewith, and which elicits a cellular immune response to HSV-2 or HSV-1, respectively, (b) a fusion protein comprising at least one above-defined fragment or variant and an unrelated sequence or comprising multiple above-defined fragments or variants and (2) a pharmaceutically acceptable carrier. |